Diamyd Medical - Developing therapies for type 1 diabetes

The focus forward into Phase III and beyond is aligned with genetics-based Precision Medicine - targeting the right individual with the right treatment at the right time.

Ulf Hannelius
President and CEO, Diamyd Medical AB
Financial Statement 19/20

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen^® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Order GAD for preclinical research

ORDER

Share This Page

GAD PRODUCTS

Order GAD for preclinical research

Developing therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd^®

Production Scientist with GMP experience

Press Releases

Events & Mediawatch

Calendar

Financial Reports

Company Presentation

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Diabetes

Products

Clinical Trials

Order GAD for preclinical research

ORDER

Annual Report

Contact Us

Subscribe

Follow Us

Developing therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd®

Production Scientist with GMP experience

Calendar

Company Presentation

THE COMPANY

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical developmentThe share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Order GAD for preclinical research

Annual Report

Follow Us

with Diamyd^®

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)